Femara 2.5mg

Femara 2.5mg contains letrozole, a non-steroidal aromatase inhibitor that reduces the body’s production of estrogen. It is primarily used in the treatment of hormone-receptor-positive breast cancer in postmenopausal women.

Letrozole works by inhibiting the aromatase enzyme responsible for converting certain androgens into estrogen. Lowering estrogen levels can help slow the growth of estrogen-dependent breast cancer cells.

Key Information

• Contains letrozole
• Non-steroidal aromatase inhibitor
• 2.5mg strength
• Oral tablet formulation
• Primarily used in hormone-sensitive breast cancer
• Prescription medicine

Active Ingredient

Letrozole

Strength

2.5mg

Dosage Form

Tablet

Medical Uses

Femara is used for the treatment of hormone-receptor-positive breast cancer in postmenopausal women. It may be used as adjuvant therapy following initial treatment or for advanced disease, depending on the clinical situation.

Letrozole is also used in certain fertility-treatment protocols under specialist supervision, although this use depends on local approval and medical guidance.

Safety Information

Letrozole significantly lowers estrogen levels and may cause hot flashes, sweating, joint or muscle pain, fatigue, headache, and nausea. Long-term estrogen suppression can contribute to reduced bone mineral density and increased fracture risk.